Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML
口服 JAK2/FLT3 抑制剂帕克替尼联合化疗治疗 FLT3-ITD 阳性 AML 的临床前活性和 I 期试点研究
期刊:Investigational New Drugs
影响因子:3
doi:10.1007/s10637-019-00786-4
Jae Yoon Jeon, Qiuhong Zhao, Daelynn R Buelow, Mitch Phelps, Alison R Walker, Alice S Mims, Sumithira Vasu, Gregory Behbehani, James Blachly, William Blum, Rebecca B Klisovic, John C Byrd, Ramiro Garzon, Sharyn D Baker, Bhavana Bhatnagar